Overview
Sangamo Q3 2025 revenue misses analyst expectations, declining significantly from last year
Net loss for Q3 2025 was $34.9 mln, compared to net income last year
Company progresses Fabry disease program, preparing for BLA submission in 2026
Outlook
Sangamo expects BLA submission for Fabry disease in Q1 2026
Company plans CTA submission for prion disease by mid-2026
Sangamo reiterates 2025 operating expenses guidance of $135 mln to $155 mln
Result Drivers
NET LOSS - Consolidated net loss for the third quarter ended September 30, 2025 was $34.9 million, or $0.11 per share, compared to net income of $10.7 million, or $0.04 per share on a fully diluted basis, for the same period in 2024
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Miss | $581,000 | $34.40 mln (5 Analysts) |
Q3 Net Income | -$34.93 mln | ||
Q3 Adjusted Operating Expenses | $33 mln | ||
Q3 Operating Expenses | $36.10 mln | ||
Q3 Operating Income | -$35.55 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Sangamo Therapeutics Inc is $2.00, about 72.5% above its November 5 closing price of $0.55
Press Release: ID:nGNX7VN1Wp
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)